Lieb K, Fiebich B L, Berger M
Abt. Psychiatrie und Psychotherapie, Universitätsklinik Freiburg.
Nervenarzt. 2000 Sep;71(9):758-61. doi: 10.1007/s001150050661.
Preclinical investigations suggest that the neuropeptide substance P might be involved in the etiopathology of pain, depression, and anxiety. In a recent study, the substance P receptor antagonist MK-869 showed antidepressant and anxiolytic activity in depressed outpatients which was comparable to a standard SSRI. The MK-869 was well tolerated. Although these findings are promising, further studies are necessary to prove the hypothesis that substance P receptor antagonists represent a new class of antidepressants or anxiolytics. Respective studies are currently underway.
临床前研究表明，神经肽P物质可能参与疼痛、抑郁和焦虑的病因学。在最近一项研究中，P物质受体拮抗剂MK-869在抑郁症门诊患者中显示出抗抑郁和抗焦虑活性，与标准的选择性5-羟色胺再摄取抑制剂相当。MK-869耐受性良好。尽管这些发现很有前景，但仍需要进一步研究来证实P物质受体拮抗剂代表一类新型抗抑郁药或抗焦虑药的假说。相关研究正在进行中。
